Investigational drug · Phase 2
MIT-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma, Oral Mucositis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "MIT-001"
First trial start
2021
Jun 21, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MIT-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma
- Oral Mucositis
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MIT-001" as an intervention, largest first.
- Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCTStatus unknown
MitoImmune TherapeuticsIndustry
NCT05493800 · 60 participants (planned) · Start Feb 1, 2022 · Primary completion Jun 30, 2024
Drug: MIT-001; normal saline · For: Oral Mucositis; Lymphoma; Multiple Myeloma and 1 more
Sites: Seoul, South Korea · 2 sites in all
- MIT-001 for Prevention of CCRT-Induced OM in HNSCC PatientsActive, not recruiting
MitoImmune TherapeuticsIndustry
NCT04651634 · 60 participants (planned) · Start Jun 21, 2021 · Primary completion Dec 31, 2025
Drug: MIT-001 plus CCRT · For: Head and Neck Squamous Cell Carcinoma; Oral Mucositis
Sites: Gilbert, Arizona; Los Angeles, California; Wichita, Kansas · 16 sites in all
MitoImmune TherapeuticsIndustry
NCT05389696 · 40 participants · Start May 13, 2022 · Primary completion Feb 13, 2023
Drug: Single subcutaneous administration and Blood collection; Single subcutaneous administration and then IV injection. and 1 more · For: Heathly Subjects
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- MIT-001, a Mitochondria-Targeted ROS Scavenger, Ameliorates DSS-Induced Colitis and Is Associated with Reduced HMGB1 and IL-1β Expression.
Kim D, Kim SH, Choe JW, et al. · Int J Mol Sci 2026
- MIT-001 mitigates vitrification-induced mitochondrial stress and regulates filamentous actin reorganization, enhancing the survival and development of vitrified-warmed bovine blastocysts.
Kim DW, Park HJ, Yang SG, et al. · J Anim Sci Technol 2026
- Population Pharmacokinetic Analysis of MIT-001, a Novel Ferroptosis Inhibitor, for Dose Optimization.
Bae S, Kim E, Rhee SJ, et al. · J Clin Pharmacol 2026
- Renoprotective Effects of MIT-001 in Ischemia-Reperfusion Injury: Modulation of Ferroptosis, ROS and Fibrotic Markers.
Shin JA, Hwang Y, Park H, et al. · J Cell Mol Med 2025
- Pharmacokinetic and Safety Profiles of MIT-001, a Novel Ferroptosis Inhibitor, After Subcutaneous Administration in Healthy Participants.
Lee S, Bae S, Yu KS, et al. · Drug Des Devel Ther 2025
- MIT-001 ameliorates ferroptosis-induced mitochondrial dysfunction and enhances embryo quality in preimplantation embryos from aged female mice.
Shim YH, Kim YJ, Ryu JS, et al. · Biomed Pharmacother 2025
Also in development for Head and Neck Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.